A source told NBC News that a funding decision could be implemented within 48 hours, though it may take longer. Advocates fear HIV cases in Colorado could rise.

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

On Wednesday, Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025).

A South African Medical Research Council (SAMRC) study has revealed that HIV remains one of the leading causes of death in the country. This is despite South Africa having the world's biggest ...